Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | GPR4 | P46093 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17586453 | 0.83 | ESR2 (0.45) | ESR2NR1H2HDAC1GPR119NPC1 | |
| SCHEMBL4917653 | 0.83 | MEN1 (0.48) | ESR2NR1H2HDAC1GPR119NPC1 | |
| SCHEMBL2109651 | 0.82 | RBP4 (0.51) | HDAC1USP30ALOX15TSHRKDM1A | |
| SCHEMBL3438854 | 0.81 | GPR119 (0.47) | ESR2NR1H2HDAC1GPR119NPC1 | |
| SCHEMBL2110412 | 0.81 | PRSS1 (0.52) | ESR2NR1H2HDAC1GPR119ALOX15 | |
| SCHEMBL31281068 | 0.80 | ESR2 (0.59) | ESR2NR1H2HDAC1GPR119NPC1 | |
| SCHEMBL12608362 | 0.80 | ESR2 (0.59) | ESR2NR1H2HDAC1GPR119NPC1 | |
| SCHEMBL20954879 | 0.80 | HDAC1 (0.46) | ESR2NR1H2HDAC1GPR119USP30 | |
| SCHEMBL327558 | 0.79 | ESR2 (0.60) | ESR2NR1H2HDAC1GPR119NPC1 | |
| SCHEMBL25322292 | 0.78 | ESR2 (0.44) | ESR2NR1H2HDAC1GPR119NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536189-B2 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-17 | — | — | US | disclosed |
| US-20120165327-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | COSTANZO MICHAEL J (US) | 2012-06-28 | — | — | US | disclosed |
| US-8158792-B2 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| EP-2224803-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2010-09-08 | — | — | EP | disclosed |
| US-20090163527-A1 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2009-06-25 | — | — | US | disclosed |
| WO-2009067202-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165327-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | TPSAB1, TPSB2, TPSD1 | ESR2 1030/4885NR1H2 686/4885HDAC1 1025/4885 |
| US-20090163527-A1 | Spiropiperidines for use as tryptase inhibitors | TPSAB1, TPSB2, TPSD1 | ESR2 1030/4885NR1H2 686/4885HDAC1 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.